Canaway, Reymark T.
HRN: 25-54-49 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/26/2024
CEFUROXIME 750MG (VIAL)
07/26/2024
08/01/2024
IV
750mg
Q8
Soft Tissue Injury
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes